Hemodynamic and symptomatic response in hypertrophic obstructive cardiomyopathy patients on myosin inhibitor therapy
Clinical and hemodynamic response to mavacamten was high in this real-world cohort and comparable to pivotal trial results. Incomplete response might be related to more severe baseline disease, which needs further study.
Authors
- Roman Pfister (ORCID: https://orcid.org/0000-0002-4358-5008)
- Athanasios Feidakis
- Richard J. Nies (ORCID: https://orcid.org/0000-0002-1336-6031)
- Monique Brüwer (ORCID: https://orcid.org/0000-0002-0152-3407)
- L Pennig
- Kenan Kaya (ORCID: https://orcid.org/0000-0002-4157-2262)
- SE Baldus
- Henrik ten Freyhaus
- Katharina Seuthe
Institutions
- University of Cologne (DE)
- University Hospital Cologne (DE)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2026-01-02
- DOI
- https://doi.org/10.3389/fcvm.2025.1639855
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00